The A-180 antibiotic is a used for the treatment of Bovine Respiratory Disease (BRD) in beef cattle. BRD is one of the most common diseases in beef cattle in North America and throughout the world (Snowder, Vleck, Cundiff, Bennet, 2006). The disease is also very costly to the beef industry in many different countries. The disease can be fatal to cattle and some of the health issues/symptoms that are associated with the illness are fever, anorexia, lethargy, pneumonia, and lung lesions (Toaff-Rosenstein, Gershwin, Tucker, 2016). Any combination or a single health issue/symptom may lead to the death of an animal. There are several different strains of the disease, that are caused by different bacterial and viruses such as; Pasteurella Multocida, Mannheimnia Hemolytica, Mycoplasma Bovis, Bovine Herpes Virus 1, … (Snowder, et al. 2006).
|
The A-180 antibiotic can not treat all the strains of the BRD and can only be used for the treatment of BRD that is associated with Mannheimia haemolytica and Pasteurella multocida (Zoetis, 2016). Also, the antibiotic can not be used on dairy cows, calves that are intended for veal, and animals that are being slaughtered for meat for human consumption within 7 days of being treated with the A-180 antibiotic (Zoetis, 2016). Finally, the A-180 antibiotic is an injectable solution that contains danofloxacin mesylate which is a synthetic fluoroquimolone antimicrobial agent (Zoetis, 2016). The antibiotic comes in both 100ml and 250ml bottles and costs approximately $437 Canadian dollars for a 250ml bottle (Advocin (danofloxacin injection) Antimicrobial for Beef Cattle - 250 ml, 2016).
|
http://countrysidenetwork.com/daily/livestock/cattle/how-to-start-a-cattle-farm-your-guide-to-breed-selection/
The A-180 antibiotic will be purchased through Zoetis Canada. Zoetis Canada is a manufacturer of a variety of products for use in the livestock industry and agriculture industry such as; vaccines, medicines, genetic tests and they are all supported by different services provided by the company (About Us, 2016). The A-180 antibiotic will be purchased from Zoetis Canada’s headquarters which is in Kirkland, Quebec, Canada. Zoetis Canada is owned by the parent company Zoetis which has its global and United States headquarters located in Parsippany, NJ, USA.
|
The company is also associated with Pfizer and has locations in over 120 countries throughout the world and reported a revenue of $504 million American dollars in 2013 (Financial Highlights, 2015). The sales of Zoetis products in Canada do not amount to a lot of Zoetis’s total sales with approximately 4% of the of company’s revenue coming from its Canadian locations (Financial Highlights, 2015). Zoetis has more than 300 different products that are produced in the 28 different manufacturing sites ran by Zoetis (Financial Highlights, 2015).
|
https://www.zoetis.ca/